Acute Pancreatitis in 2 Adolescent Boys on Dupilumab Therapy for Atopic Dermatitis

Stoner, Ryan C.; Ophaug, Solveig; Simpson, Eric L.; Hanifin, Jon M.

doi:10.1097/der.0000000000000651

Cited by 7 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first case report was associated with the development of pancreatitis in 2 adolescent boys. 11 However, there was no recurrence on rechallenge, and they were both historically on medication that has been previously associated with pancreatitis. The second case report was described in a 40-year-old man after administration of his second dose of dupilumab.…”

Section: Discussionmentioning

confidence: 95%

Dupilumab-Induced Pancreatitis

Jasti

McCarthy²,

Govani³

2023

ACG Case Rep J

View full text Add to dashboard Cite

Drug-induced pancreatitis (DIP) is a rare cause of pancreatitis with an extensive and growing list of offending medications. Drawing a causative relationship between a medication and pancreatitis can be challenging, requiring a thorough workup to exclude other potential etiologies. By using scoring systems to identify DIP, we have identified another case of suspected DIP. In this study, we present a case of pancreatitis 10 days after initiation of dupilumab. An evaluation for other causes was unrevealing. As dupilumab use increases, providers should be aware of this possible adverse effect.

show abstract

Section: Discussionmentioning

confidence: 95%

Dupilumab-Induced Pancreatitis

Jasti

McCarthy²,

Govani³

2023

ACG Case Rep J

View full text Add to dashboard Cite

show abstract

“…One reason for this being the immunosuppressive effect of the therapy, which could increase the risk of developing infected necrosis during an acute episode of pancreatitis. Furthermore, acute pancreatitis was reported as a very rare side effect of treatment with Dupilumab ( 122 ).…”

Section: Chronic Pancreatitismentioning

confidence: 99%

Immune response mechanisms in acute and chronic pancreatitis: strategies for therapeutic intervention

Glaubitz,

Asgarbeik,

Lange

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Acute pancreatitis (AP) is one of the most common inflammatory diseases of the gastrointestinal tract and a steady rising diagnosis for inpatient hospitalization. About one in four patients, who experience an episode of AP, will develop chronic pancreatitis (CP) over time. While the initiating causes of pancreatitis can be complex, they consistently elicit an immune response that significantly determines the severity and course of the disease. Overall, AP is associated with a significant mortality rate of 1-5%, which is caused by either an excessive pro-inflammation, or a strong compensatory inhibition of bacterial defense mechanisms which lead to a severe necrotizing form of pancreatitis. At the time-point of hospitalization the already initiated immune response is the only promising common therapeutic target to treat or prevent a severe disease course. However, the complexity of the immune response requires fine-balanced therapeutic intervention which in addition is limited by the fact that a significant proportion of patients is in danger of development or progress to recurrent and chronic disease. Based on the recent literature we survey the disease-relevant immune mechanisms and evaluate appropriate and promising therapeutic targets for the treatment of acute and chronic pancreatitis.

show abstract

“…4,5 There have also been several case reports that suggest that dupilumab may cause metabolic changes in rare cases. Dupilumab-associated acute pancreatitis has been reported in two otherwise healthy adolescent males, 6 and dupilumab has also been reported to be associated with the development of type I diabetes. 7 Our patient presented with asymptomatic darkening of intertriginous areas that are classically associated with AN.…”

Section: Introduction Case Reportmentioning

confidence: 96%

Dupilumab-induced Acanthosis Nigricans

Yaghi,

Ju,

et al. 2024

J of Skin

View full text Add to dashboard Cite

Dupilumab is a human monoclonal IgG4 antibody to interleukin-4 (IL-4) and IL-13 approved for the treatment of moderate-to-severe atopic dermatitis (AD) in patients six months or older. Several cutaneous adverse reactions to dupilumab have been reported, including facial dermatitis and psoriasis. Herein, we present a unique case of dupilumab-induced acanthosis nigricans (AN) in a patient treated for concomitant AD and contact dermatitis, in the absence of other associated conditions or potential culprit medications. The patient had complete resolution of the lesions with discontinuation of medication, and recurrence upon re-initiation of therapy. This case represents a new cutaneous adverse reaction to dupilumab to which dermatologists should be familiar.

show abstract

Acute Pancreatitis in 2 Adolescent Boys on Dupilumab Therapy for Atopic Dermatitis

Cited by 7 publications

References 6 publications

Dupilumab-Induced Pancreatitis

Dupilumab-Induced Pancreatitis

Immune response mechanisms in acute and chronic pancreatitis: strategies for therapeutic intervention

Dupilumab-induced Acanthosis Nigricans

Contact Info

Product

Resources

About